drugset / Trial / NCT00677053
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and tolerability of multiple doses of TAK-442once daily, (QD) or twice daily (BID), in subjects with acute coronary syndrome (unstable angina, myocardial infarction).
Timeline
- Start
- 2008-03
- Primary completion
- 2010-06
- Completion
- 2010-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LETAXABAN | Small molecule | 10 mg | Oral |
| Subject | LETAXABAN | Small molecule | 20 mg | Oral |
| Subject | LETAXABAN | Small molecule | 40 mg | Oral |
| Subject | LETAXABAN | Small molecule | 80 mg | Oral |
| Subject | LETAXABAN | Small molecule | 120 mg | Oral |
| Subject | LETAXABAN | Small molecule | 160 mg | Oral |